US Senate Panel Warns of China's Increasing Control Over Pharmaceutical Supply Chain
A bipartisan US Senate commission, the National Security Commission on Emerging Biotechnology, has released a report warning that China is aggressively expanding its control over the global pharmaceutical supply chain. The panel notes that Chinese influence spans from basic medicine manufacturing to the discovery of novel treatments, creating a strategic vulnerability for the United States. The report highlights a growing dependency, noting that nearly 40% of drugs currently in development originated in China. This trend is exacerbated by multinational pharmaceutical companies increasingly entering into agreements with Chinese biotech firms for early-stage drug candidates, such as Pfizer's deal with Starna and Novartis's partnership with Abogen.

Topics: biotechnology security national security pharmaceutical supply chain US-China relations